Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 13/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399748 | 1.00 | DGAT1 (0.51) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL16969309 | 0.88 | DGAT1 (0.42) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL17327330 | 0.86 | ESR2 (0.56) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL10197496 | 0.86 | DGAT1 (0.47) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL382898 | 0.86 | ESR2 (0.56) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL382897 | 0.86 | ESR2 (0.56) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL14113473 | 0.85 | DGAT1 (0.48) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL3302329 | 0.85 | DGAT1 (0.48) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL3302331 | 0.85 | DGAT1 (0.48) | DGAT1ALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL3307324 | 0.85 | ALDH1A1 (0.50) | DGAT1ALDH1A1LMNAMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-118344370-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| CN-101466690-A | (trans-4- [ ({5- [ (3)) | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
| CN-101460492-A | Benzimidazoles and their use for the treatment of diabetes | ASTRAZENECA AB (SE) | 2009-06-17 | — | — | CN | disclosed |
| EP-2041101-A1 | CRYSTALLINE FORM OF (TRANS-4- [ ( { 5- [ (3, 4 -DI FLUOROPHENYL) AMINO]-1,3, 4-OXADIAZOL-2-YL}CARBONYL) AMINO]PH ENYL } CYCLOHEXYL) ACETIC ACID | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2032546-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Astra Zeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008129319-A1 | SALTS OF OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007144571-A1 | CRYSTALLINE FORM OF (TRANS-4- [ ( { 5- [ (3, 4 -DI FLUOROPHENYL) AMINO] -1,3, 4-OXADIAZOL-2-YL}CARBONYL) AMINO] PH ENYL } CYCLOHEXYL) ACETIC ACID | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007141538-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141538-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | DGAT1 1/4885ALDH1A1 112/4885LMNA 3400/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | DGAT1 3646/4885ALDH1A1 2283/4885LMNA 4331/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DGAT1 3646/4885ALDH1A1 2283/4885LMNA 4331/4885 |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DGAT1 3646/4885ALDH1A1 2283/4885LMNA 4331/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DGAT1 4038/4885ALDH1A1 2446/4885LMNA 3480/4885 |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | DGAT1 3646/4885ALDH1A1 2283/4885LMNA 4331/4885 |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | DGAT1 3646/4885ALDH1A1 2283/4885LMNA 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.